Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19
Background: Castleman disease (CD) is a rare lymphoproliferative disorder with various subtypes, including the HHV-8-negative/idiopathic multicentric CD (iMCD). The diagnosis of iMCD remains challenging due to its non-specific presentation, in the form of generalised lymphadenopathies and inflammati...
Main Authors: | Helbies Bedier, Stéphane Isnard, Chelsea Maedler-Kron, Jean-Pierre Routy |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2023-11-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/4098 |
Similar Items
-
Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences
by: Bernardo Rossini, et al.
Published: (2024-03-01) -
Are patients with HHV-8 associated Castleman disease successfully treated with rituximab at risk of subsequently developing HHV-8 negative (idiopathic) Castleman disease?
by: Gavin Ha, et al.
Published: (2023-06-01) -
A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report
by: Magdalena Strach, et al.
Published: (2023-10-01) -
Variant of plasmablastic microlymphoma in Castleman disease: a case report and review of the literature
by: Nathan Artom, et al.
Published: (2018-12-01) -
Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
by: Christian Hoffmann, et al.
Published: (2022-10-01)